Long-term retention rate of anakinra in adult onset Still's disease and predictive factors for treatment response

Key Findings

• ●Anakinra retention rate: cumulative loss-of-efficacy risk 3.4% at 12 months, 13.5% at 60 months
• ●14.2% discontinued due to long-term treatment-induced remission

Referenced in (1 disease)